Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Giulia Carli, Taylor Brown, Fotini Michalakis, Abigail M Biddix, Stiven Roytman, Robert Vangel, August Van Hout, Prabesh Kanel, Peter J. H. Scott, Roger L. Albin, Nicolaas Ida Bohnen
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Neuropathology of Parkinson disease
10.1016/j.parkreldis.2017.07.033 · 2018
Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state
10.1093/brain/awab446 · 2022
White matter changes in Parkinson’s disease
10.1038/s41531-023-00592-z · 2023
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
10.1016/s1474-4422(13)70124-8 · 2013
Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations
10.1136/jnnp.2009.204685 · 2011
Cerebral small vessel disease: A review of clinical, radiological, and histopathological phenotypes
10.1111/j.1747-4949.2011.00725.x · 2012
Pathogenesis of leukoaraiosis: A review
10.1161/01.str.28.3.652 · 1997
What are white matter hyperintensities made of? Relevance to vascular cognitive impairment
10.1161/jaha.114.001140 · 2015
Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study
10.1007/s00401-003-0676-3 · 2003
Extracranial arterial wall volume is increased and shows relationships with vascular MRI measures in idiopathic Parkinson’s disease
10.1016/j.clineuro.2018.02.013 · 2018
Progression of white matter hyperintensities in Alzheimer disease, dementia with Lewy bodies, and Parkinson disease dementia: A comparison with normal aging
10.1097/01.jgp.0000236596.56982.1c · 2006
Modifiable vascular risk factors, white matter disease and cognition in early Parkinson’s disease
10.1111/ene.13797 · 2019
White matter hyperintensities are linked to future cognitive decline in de novo Parkinson’s disease patients
10.1016/j.nicl.2018.09.025 · 2018
Cross-sectional and longitudinal associations between total and regional white matter hyperintensity volume and cognitive and motor function in Parkinson’s disease
10.1016/j.nicl.2019.101870 · 2019
Brain atrophy and white matter hyperintensities in early Parkinson’s disease
10.1002/mds.22754 · 2009
Age- and disease-related cerebral white matter changes in patients with Parkinson’s disease
10.1016/j.neurobiolaging.2019.05.004 · 2019
White matter hyperintensities in patients with Parkinson’s disease: A systematic review and meta-analysis
10.1016/j.jns.2021.117481 · 2021
Effects of white matter hyperintensity on cognitive function in PD patients: A meta-analysis
10.3389/fneur.2023.1203311 · 2023
The contribution of white matter lesions to Parkinson’s disease motor and gait symptoms: A critical review of the literature
10.1007/s00702-015-1470-9 · 2016
Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections
2009
A multicenter longitudinal study of cholinergic subgroups in Parkinson disease
10.1038/s41467-025-60815-0 · 2025
Progression of regional cortical cholinergic denervation in Parkinson’s disease
10.1093/braincomms/fcac320 · 2022
Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus
10.1002/cne.903230209 · 1992
Unresolved referenced work
2004
Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson’s disease
10.1016/bs.pbr.2022.01.011 · 2022
The cholinergic brain in Parkinson’s disease
10.1002/mdc3.13319 · 2021
Cholinergic system changes in Parkinson’s disease: Emerging therapeutic approaches
10.1016/s1474-4422(21)00377-x · 2022
Cholinergic denervation patterns across cognitive domains in Parkinson’s disease
10.1002/mds.28360 · 2021
Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease
10.1093/brain/awy072 · 2018
Cholinergic denervation patterns in Parkinson’s disease associated with cognitive impairment across domains
2025
Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease
10.1093/brain/awad420 · 2024
A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia
10.1161/01.str.0000183615.07936.b6 · 2005
Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain
10.1093/brain/121.12.2249 · 1998
White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers
10.3389/fneur.2023.1100322 · 2023
White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer’s disease
2023
Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders
10.1186/s13195-024-01536-2 · 2024
Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients
10.1001/archneur.64.2.266 · 2007
Differential cholinergic pathway involvement in Alzheimer’s disease and subcortical ischemic vascular dementia
10.3233/jad-122320 · 2013
Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson’s disease patients according to cognitive status
10.1136/jnnp-2011-300872 · 2012
Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism
10.1016/j.jns.2015.03.046 · 2015
Parkinson disease-associated cognitive impairment
10.1038/s41572-021-00280-3 · doi-reference
Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naïve Parkinson’s disease
10.1016/j.parkreldis.2022.02.020 · doi-reference
Differential spatial distribution of white matter lesions in Parkinson’s and Alzheimer’s diseases and cognitive sequelae
10.1007/s00702-022-02519-z · doi-reference
Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: Removing axonal debris
10.1186/s40035-021-00262-1 · doi-reference
Diabetes mellitus and white matter hyperintensity
10.1111/ggi.12666 · doi-reference
White matter microstructure in Parkinson’s disease with and without elevated rapid eye movement sleep muscle tone
10.1093/braincomms/fcac027 · doi-reference
Fiber pathways of basal forebrain cholinergic neurons in monkeys
10.1016/0006-8993(87)90783-9 · doi-reference
White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia
10.3389/fnagi.2017.00047 · doi-reference
White matter lesions in Parkinson disease
10.1038/nrneurol.2011.21 · doi-reference
A robust bootstrap test for mediation analysis
10.1177/1094428121999096 · doi-reference
Mediation: R package causal mediation analysis
10.18637/jss.v059.i05 · doi-reference
Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification
10.1016/j.neuroimage.2007.07.053 · doi-reference
Reproducibility of quantitative tractography methods applied to cerebral white matter
10.1016/j.neuroimage.2007.02.049 · doi-reference
Performance of three freely available methods for extracting white matter hyperintensities: FreeSurfer, UBO detector, and BIANCA
10.1002/hbm.25739 · doi-reference
UBO detector – A cluster-based, fully automated pipeline for extracting white matter hyperintensities
10.1016/j.neuroimage.2018.03.050 · doi-reference
Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects
10.1038/jcbfm.1992.81 · doi-reference
Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV
10.1038/s41380-018-0130-5 · doi-reference
A deep learning toolbox for automatic segmentation of subcortical limbic structures from MRI images
10.1016/j.neuroimage.2021.118610 · doi-reference
In vivo imaging of human cholinergic nerve terminals with (-)-5-18F-fluoroethoxybenzovesamicol: Biodistribution, dosimetry, and tracer kinetic analyses
10.2967/jnumed.113.124792 · doi-reference
Highlighting the versatility of the tracerlab synthesis modules. Part 1: Fully automated production of [18F] labelled radiopharmaceuticals using a Tracerlab FXFN
10.1002/jlcr.1865 · doi-reference
Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study
10.1016/j.nbas.2022.100039 · doi-reference
Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease
10.1093/braincomms/fcab109 · doi-reference
Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines
10.1002/mds.24893 · doi-reference
Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases
10.1136/jnnp.55.3.181 · doi-reference
Cholinergic changes in Lewy body disease: Implications for presentation, progression and subtypes
10.1093/brain/awae069 · doi-reference
The white matter hyperintensities within the cholinergic pathways and cognitive performance in patients with Parkinson’s disease after bilateral STN DBS
10.1016/j.jns.2020.117121 · doi-reference